‘Watermelon’ or red snow has puzzled mountain climbers, explorers, and naturalists for thousands of years. Observed globally in alpine and polar regions during the summer, it is caused by blooms of microscopic algae and their […]
OxThera AB, a Stockholm-based privately-held biopharmaceutical companyand leader in the field of microbiome derived biotherapeutics, today announced a poster presentation showing encouraging Oxabact® efficacy and safety data from the long-term study OC5-OL-01, at the Annual […]
In the largest clinical microbiome study in infants reported to date, a team led by researchers at Baylor College of Medicine explored the sequence of microbial colonization in the infant gut through age 4 and […]
Microbiotica, a leading player in microbiome-based therapeutics, announced that it has attracted an equity investment from Seventure Partners, a leading investor in the microbiome space. This new investment of £4m brings the total equity raised […]
ConsortiaTX, Inc., a bio-therapeutics startup developing and commercializing microbial therapies to prevent and treat human disease and allergies, has signed an agreement with Brigham and Women’s Hospital (BWH) and Boston Children’s Hospital for an exclusive, […]
The tiny microbes located inside the intestines could play a critical role in heart attack recovery, according to a new study that found gut bacteria helpful in repairing the damage after a heart attack. But […]
ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company […]
With a growing body of science linking gut microbiota to inflammatory bowel disease (IBD), a need exists in clinical settings to understand changes in the gut microbial community as they relate to IBD and its […]
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded three Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), […]
Patients with cystic fibrosis (CF), a genetic disease that causes a persistent buildup of thick mucus in their lungs and other organs, suffer from chronic bacterial infections and inflammation that often lead to deadly respiratory […]
LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery announced that it has signed an exclusive license agreement with Cornell University (Ithaca, NY, USA ) for its Christensenella patent family. Christensenella is a recently […]